EP1589934A4 - Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung - Google Patents
Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendungInfo
- Publication number
- EP1589934A4 EP1589934A4 EP04700403A EP04700403A EP1589934A4 EP 1589934 A4 EP1589934 A4 EP 1589934A4 EP 04700403 A EP04700403 A EP 04700403A EP 04700403 A EP04700403 A EP 04700403A EP 1589934 A4 EP1589934 A4 EP 1589934A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- phosphate compounds
- aminoalkyl glucosaminide
- glucosaminide phosphate
- certain aminoalkyl
- certain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15161799.0A EP2940028B8 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
SI200432284T SI1589934T1 (sl) | 2003-01-06 | 2004-01-06 | Določene aminoalkil glukozaminid fosfat spojine in njih uporaba |
CY20151101158T CY1117129T1 (el) | 2003-01-06 | 2015-12-17 | Συγκεκριμενες φωσφορικες ενωσεις αμυναλκιλικου γλυκοζαμινιδιου και η χρηση τους |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43858503P | 2003-01-06 | 2003-01-06 | |
US438585P | 2003-01-06 | ||
PCT/US2004/000377 WO2004062599A2 (en) | 2003-01-06 | 2004-01-06 | Certain aminoalkyl glucosaminide phosphate compounds and their use |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15161799.0A Division-Into EP2940028B8 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
EP15161799.0A Division EP2940028B8 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1589934A2 EP1589934A2 (de) | 2005-11-02 |
EP1589934A4 true EP1589934A4 (de) | 2011-09-07 |
EP1589934B1 EP1589934B1 (de) | 2015-09-23 |
Family
ID=32713348
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15161799.0A Expired - Lifetime EP2940028B8 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
EP04700403.1A Expired - Lifetime EP1589934B1 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15161799.0A Expired - Lifetime EP2940028B8 (de) | 2003-01-06 | 2004-01-06 | Bestimmte aminoalkyl-glucosaminid-phosphatverbindungen und ihre verwendung |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP2940028B8 (de) |
JP (2) | JP4838706B2 (de) |
KR (2) | KR20110120989A (de) |
CN (2) | CN101863930A (de) |
AU (1) | AU2004204754B2 (de) |
BR (1) | BRPI0406628A (de) |
CA (1) | CA2512108C (de) |
CY (1) | CY1117129T1 (de) |
DK (1) | DK1589934T3 (de) |
ES (2) | ES2639812T3 (de) |
HK (2) | HK1217104A1 (de) |
HU (1) | HUE026376T2 (de) |
IL (1) | IL169540A (de) |
MX (1) | MXPA05007295A (de) |
PL (1) | PL220536B1 (de) |
PT (1) | PT1589934E (de) |
RU (3) | RU2544850C2 (de) |
SI (1) | SI1589934T1 (de) |
WO (1) | WO2004062599A2 (de) |
ZA (1) | ZA200505302B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CA2512108C (en) * | 2003-01-06 | 2013-04-02 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
EP1853227B1 (de) * | 2005-03-02 | 2009-08-05 | The Secretary of State for Defence | Pharmazeutische zusammensetzung |
GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
BE1021939B1 (fr) | 2013-03-15 | 2016-01-27 | Glaxosmithkline Biologicals S.A. | Composition pour des composes aminoalkylglucosaminide phosphate tamponnes et son utilisation. |
PL3116887T3 (pl) | 2014-03-13 | 2021-09-06 | Universität Basel | Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną |
JP2018509384A (ja) * | 2015-01-06 | 2018-04-05 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドImmunovaccine Technologies Inc. | リピドa模倣体、調製方法、及びその使用 |
CN108026134A (zh) * | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
EP3886901A1 (de) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Verfahren zur herstellung eines adjuvans |
BR112022000710A2 (pt) | 2019-07-21 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Vacina viral terapêutica |
US20230234992A1 (en) | 2020-06-05 | 2023-07-27 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
BR112022025969A2 (pt) | 2020-06-22 | 2023-01-17 | Sumitomo Pharma Co Ltd | Adjuvante com atividade agonista de tlr4 |
EP4032547A1 (de) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce abgeleitete fragemente zur hsv therapie |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001034617A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
DE10399031I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
JPH01180896A (ja) * | 1988-01-08 | 1989-07-18 | Toho Yakuhin Kogyo Kk | 新規ホスホリルグルコサミン誘導体 |
EP0359789B1 (de) | 1988-01-21 | 1993-08-04 | Genentech, Inc. | Verstärkung und nachweis von nukleinsäuresequenzen |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5597573A (en) * | 1989-05-04 | 1997-01-28 | Igen, Inc. | Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
EP1001032A3 (de) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern |
KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | タンパク質マイクロスフェア組成物 |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DK0500799T3 (da) | 1989-11-16 | 1998-09-14 | Univ Duke | Partikel-medieret transformation af animalske vævsceller |
FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
US5593969A (en) * | 1991-09-03 | 1997-01-14 | Igen Incorporated | Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors |
US5530113A (en) | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
EP0641192B1 (de) | 1992-05-18 | 1997-07-23 | Minnesota Mining And Manufacturing Company | Einrichtung zur transmucosalen wirkstoffabgabe |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
FR2702160B1 (fr) | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
FR2704145B1 (fr) | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
CA2158733C (en) | 1994-01-21 | 2007-01-16 | Dennis E. Mccabe | Gas driven gene delivery instrument |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
PT772619E (pt) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | Oligonucleotidos imunomoduladores |
FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
EP0832282A1 (de) | 1995-06-02 | 1998-04-01 | Incyte Pharmaceuticals, Inc. | VERBESSERTER VERFAHREN ZUR HERSTELLUNG VON cDNA-SEQUENZEN MIT VOLLER LÄNGER |
US5750664A (en) * | 1995-06-05 | 1998-05-12 | Eisai Co., Ltd. | Substituted liposaccharides useful in the treatment and prevention of endotoxemia |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
WO1997007788A2 (en) | 1995-08-31 | 1997-03-06 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US6355257B1 (en) * | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
KR100241901B1 (ko) | 1997-08-28 | 2000-02-01 | 윤종용 | 핸드셋과 핸즈프리킷 공용 음성인식기의 등록 엔트리 관리방법 |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
US6355251B1 (en) | 1999-06-15 | 2002-03-12 | Mark Zamoyski | Compositions and methods for epidermal chemexfoliation |
WO2001032667A1 (fr) * | 1999-11-04 | 2001-05-10 | Sankyo Company, Limited | Analogues de gla-60 du type de l'ether |
CA2396744C (en) * | 1999-11-15 | 2011-07-12 | Biomira, Inc. | Synthetic lipid-a analogs and uses thereof |
EP1284740B1 (de) | 2000-05-19 | 2008-05-21 | Corixa Corporation | Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren |
ES2261453T3 (es) | 2000-08-04 | 2006-11-16 | Corixa Corporation | Nuevos compuestos inmunoefectores. |
MXPA05000407A (es) * | 2002-07-08 | 2005-04-19 | Corixa Corp | Procedimientos para la produccion de fosfato de aminoalquilglucosaminida e inmunoefectores de disacarido, e intermediarios para los mismos. |
CA2512108C (en) * | 2003-01-06 | 2013-04-02 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2004
- 2004-01-06 CA CA2512108A patent/CA2512108C/en not_active Expired - Fee Related
- 2004-01-06 ES ES15161799.0T patent/ES2639812T3/es not_active Expired - Lifetime
- 2004-01-06 PL PL380950A patent/PL220536B1/pl unknown
- 2004-01-06 ZA ZA200505302A patent/ZA200505302B/en unknown
- 2004-01-06 PT PT47004031T patent/PT1589934E/pt unknown
- 2004-01-06 HU HUE04700403A patent/HUE026376T2/en unknown
- 2004-01-06 WO PCT/US2004/000377 patent/WO2004062599A2/en active Application Filing
- 2004-01-06 BR BR0406628-6A patent/BRPI0406628A/pt not_active Application Discontinuation
- 2004-01-06 SI SI200432284T patent/SI1589934T1/sl unknown
- 2004-01-06 RU RU2009140730/04A patent/RU2544850C2/ru active
- 2004-01-06 KR KR1020117025068A patent/KR20110120989A/ko not_active Application Discontinuation
- 2004-01-06 CN CN201010168144A patent/CN101863930A/zh active Pending
- 2004-01-06 EP EP15161799.0A patent/EP2940028B8/de not_active Expired - Lifetime
- 2004-01-06 JP JP2006500845A patent/JP4838706B2/ja not_active Expired - Fee Related
- 2004-01-06 MX MXPA05007295A patent/MXPA05007295A/es active IP Right Grant
- 2004-01-06 AU AU2004204754A patent/AU2004204754B2/en not_active Ceased
- 2004-01-06 KR KR1020057012606A patent/KR101110889B1/ko active IP Right Grant
- 2004-01-06 CN CNA2004800030660A patent/CN101080234A/zh active Pending
- 2004-01-06 ES ES04700403.1T patent/ES2556970T3/es not_active Expired - Lifetime
- 2004-01-06 EP EP04700403.1A patent/EP1589934B1/de not_active Expired - Lifetime
- 2004-01-06 RU RU2005125050/04A patent/RU2389732C2/ru active
- 2004-01-06 DK DK04700403.1T patent/DK1589934T3/en active
-
2005
- 2005-07-05 IL IL169540A patent/IL169540A/en active IP Right Grant
-
2006
- 2006-04-26 HK HK16105081.1A patent/HK1217104A1/zh not_active IP Right Cessation
- 2006-04-26 HK HK06104986.2A patent/HK1083593A1/xx not_active IP Right Cessation
-
2011
- 2011-07-15 JP JP2011156294A patent/JP2011246481A/ja active Pending
-
2015
- 2015-02-06 RU RU2015104031A patent/RU2015104031A/ru not_active Application Discontinuation
- 2015-12-17 CY CY20151101158T patent/CY1117129T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001034617A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
Non-Patent Citations (2)
Title |
---|
PERSING, DAVID H. ET AL: "Taking toll: lipid A mimetics as adjuvants and immunomodulators", TRENDS IN MICROBIOLOGY , 10(10, SUPPL.), S32-S37 CODEN: TRMIEA; ISSN: 0966-842X, 2002, XP009067296 * |
See also references of WO2004062599A2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217105A1 (zh) | 些氨基烷基氨基葡糖苷磷酸酯化合物及其用途 | |
IL169540A0 (en) | Certain aminoalkyl glucosaminide phosphate compounds and their use | |
GB0300805D0 (en) | Compounds and their use | |
GB0300804D0 (en) | Compounds and their use | |
GB0301143D0 (en) | Compounds and their use | |
GB0317133D0 (en) | Compounds and their use | |
GB0322194D0 (en) | Compounds and their medical uses | |
GB0322195D0 (en) | Compounds and their medical uses | |
GB0316114D0 (en) | Compounds and their use | |
GB0310471D0 (en) | Compounds and their use | |
GB0310333D0 (en) | Compounds and their use | |
GB0314295D0 (en) | Compounds and their use | |
GB0316112D0 (en) | Compounds and their use | |
GB0316090D0 (en) | Compounds and their use | |
GB0316203D0 (en) | Compounds and their use | |
GB0314293D0 (en) | Compounds and their use | |
GB0314292D0 (en) | Compounds and their use | |
GB0309320D0 (en) | Compounds and their use | |
GB0314291D0 (en) | Compounds and their use | |
GB0316204D0 (en) | Compounds and their use | |
GB0316205D0 (en) | Compounds and their use | |
GB0320064D0 (en) | Compounds and their use | |
GB0310472D0 (en) | Compounds and their use | |
GB0316108D0 (en) | Compounds and their use | |
GB0310470D0 (en) | Compounds and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050805 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1083593 Country of ref document: HK |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7008 20060101AFI20070130BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602004047937 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031700800 Ipc: C07H0015040000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110805 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07H 15/04 20060101AFI20110801BHEP |
|
17Q | First examination report despatched |
Effective date: 20120127 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150120 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150416 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CORIXA CORPORATION |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 751181 Country of ref document: AT Kind code of ref document: T Effective date: 20151015 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602004047937 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MICHELI AND CIE SA, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20151214 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2556970 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160121 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20151221 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E011431 Country of ref document: EE Effective date: 20151222 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1083593 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602004047937 Country of ref document: DE Representative=s name: HERNANDEZ, YORCK, DIPL.-ING., DE |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E026376 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 20087 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20150402681 Country of ref document: GR Effective date: 20160414 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602004047937 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20160624 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 751181 Country of ref document: AT Kind code of ref document: T Effective date: 20150923 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: HC Owner name: CORIXA CORPORATION; US Free format text: FORMER OWNER: CORIXA CORPORATION Effective date: 20180110 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CA Effective date: 20180509 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20201230 Year of fee payment: 18 Ref country code: PT Payment date: 20201230 Year of fee payment: 18 Ref country code: CZ Payment date: 20201228 Year of fee payment: 18 Ref country code: CH Payment date: 20201228 Year of fee payment: 18 Ref country code: BG Payment date: 20201230 Year of fee payment: 18 Ref country code: EE Payment date: 20201221 Year of fee payment: 18 Ref country code: GB Payment date: 20201231 Year of fee payment: 18 Ref country code: FI Payment date: 20201230 Year of fee payment: 18 Ref country code: IE Payment date: 20201230 Year of fee payment: 18 Ref country code: GR Payment date: 20201230 Year of fee payment: 18 Ref country code: FR Payment date: 20201223 Year of fee payment: 18 Ref country code: DK Payment date: 20201230 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20201223 Year of fee payment: 18 Ref country code: BE Payment date: 20201228 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20201228 Year of fee payment: 18 Ref country code: NL Payment date: 20201228 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210121 Year of fee payment: 18 Ref country code: CY Payment date: 20201222 Year of fee payment: 18 Ref country code: MC Payment date: 20210105 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20201218 Year of fee payment: 18 Ref country code: TR Payment date: 20210106 Year of fee payment: 18 Ref country code: SI Payment date: 20201221 Year of fee payment: 18 Ref country code: SE Payment date: 20210111 Year of fee payment: 18 Ref country code: AT Payment date: 20201230 Year of fee payment: 18 Ref country code: HU Payment date: 20210109 Year of fee payment: 18 Ref country code: ES Payment date: 20210201 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004047937 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: MAE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20220131 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 20087 Country of ref document: SK Effective date: 20220106 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20220201 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: MM4A Ref document number: E011431 Country of ref document: EE Effective date: 20220131 Ref country code: AT Ref legal event code: MM01 Ref document number: 751181 Country of ref document: AT Kind code of ref document: T Effective date: 20220106 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20220106 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220107 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220706 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220201 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220805 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220802 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220731 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220107 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220107 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: KO00 Effective date: 20220930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220106 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220107 |